Department of Surgery, University of Toronto, Toronto, ON, Canada.
Surgery B, Sheba Medical Center, Tel Hashomer, 52621, Ramat Gan, Israel.
Breast Cancer Res Treat. 2020 Dec;184(3):763-770. doi: 10.1007/s10549-020-05895-w. Epub 2020 Aug 26.
The Ontario High Risk Breast Screening program follows women aged 30-69 at an increased risk of breast cancer, using a yearly mammography and breast MRI. The aim of this study is to determine the clinical outcomes for the enrolled women.
Observational cohort study following 2081 participants in the high-risk screening program 2011-2017. The participants were divided into three subgroup according to their risk criteria: (a) known carriers of pathogenic variants (PV) in hereditary breast cancer genes. (b) Previous chest radiotherapy. (c) Estimated life time risk (ELR) ≥ 25%, calculated using the International Breast Cancer Intervention Study (IBIS) tool, with no known mutation or previous radiation. All Breast Cancer (BC) diagnosed during the follow-up time were recorded.
673 women carried PVs in hereditary breast cancer genes, 159 had a history of chest radiotherapy, and 1249 had an ELR ≥ 25%. The total cohort of screening years was 8126. Median age at BC diagnosis was 41 for the first group, 47 for the second group and 51 for the third. BC incidence rate was 18.2 for PV mutation carriers, 17.9 for the chest radiotherapy group and 6.2 for ELR ≥ 25%. Hazard ratio was similar for the first two groups, but significantly lower for the ELR ≥ 25% group. When stratifying by age, the incidence rate in the ELR ≥ 25% increased over time, until it became similar to that of the other subgroups after age 50.
Our findings question the need to screen women with an elevated lifetime risk using the same screening practices used for women who are PV mutation carriers, or with a history of chest radiation, prior to the age of 50.
安大略高危乳腺癌筛查项目针对乳腺癌风险增加的 30-69 岁女性,每年进行一次乳房 X 光检查和乳房 MRI。本研究的目的是确定入组女性的临床结局。
对 2011-2017 年高危筛查项目的 2081 名参与者进行观察性队列研究。根据风险标准将参与者分为三组:(a)已知携带遗传性乳腺癌基因致病性变异(PV)的患者。(b)既往胸部放疗。(c)使用国际乳腺癌干预研究(IBIS)工具计算的终生风险(ELR)≥25%,无已知突变或既往放射治疗。随访期间所有诊断的乳腺癌(BC)均被记录。
673 名女性携带遗传性乳腺癌基因的 PV,159 名有胸部放疗史,1249 名 ELR≥25%。整个筛查年度数为 8126 年。第一组的 BC 诊断中位年龄为 41 岁,第二组为 47 岁,第三组为 51 岁。BC 发病率为 PV 突变携带者 18.2%,胸部放疗组 17.9%,ELR≥25%组 6.2%。前两组的危险比相似,但 ELR≥25%组明显降低。按年龄分层时,ELR≥25%组的发病率随时间增加,直到 50 岁后与其他亚组相似。
我们的研究结果表明,在 50 岁之前,对于使用相同的筛查实践筛查携带高终生风险的女性,或有胸部辐射史的女性,可能不需要筛查携带高终生风险的女性。